FGF21 and metabolic dysfunction-associated steatohepatitis: Deficiency of FGF21 favors the development of steatosis, inflammation, hepatocyte injury and fibrosis in the liver, while administration of FGF21 analogues improves NASH by attenuating these processes (274).